Show simple item record

dc.contributor.authorJames, N
dc.contributor.authorSydes, M
dc.contributor.authorClarke, Noel W
dc.contributor.authorMason, M
dc.contributor.authorDearnaley, D
dc.contributor.authorSpears, M
dc.contributor.authorRitchie, A
dc.contributor.authorParker, C
dc.contributor.authorRussell, J
dc.contributor.authorAttard, G
dc.contributor.authorde Bono, J
dc.contributor.authorCross, W
dc.contributor.authorJones, R
dc.contributor.authorThalmann, G
dc.contributor.authorAmos, CL
dc.contributor.authorMatheson, D
dc.contributor.authorMillman, R
dc.contributor.authorAlzouebi, M
dc.contributor.authorBeesley, S
dc.contributor.authorBirtle, A
dc.contributor.authorBrock, S
dc.contributor.authorCathomas, R
dc.contributor.authorChakraborti, P
dc.contributor.authorChowdhury, S
dc.contributor.authorCook, A
dc.contributor.authorElliott, T
dc.contributor.authorGale, J
dc.contributor.authorGibbs, S
dc.contributor.authorGraham, J
dc.contributor.authorHetherington, J
dc.contributor.authorHughes, R
dc.contributor.authorLaing, R
dc.contributor.authorMcKinna, F
dc.contributor.authorMcLaren, D
dc.contributor.authorO'Sullivan, J
dc.contributor.authorParikh, O
dc.contributor.authorPeedell, C
dc.contributor.authorProtheroe, A
dc.contributor.authorRobinson, A
dc.contributor.authorSrihari, N
dc.contributor.authorSrinivasan, R
dc.contributor.authorStaffurth, J
dc.contributor.authorSundar, S
dc.contributor.authorTolan, S
dc.contributor.authorTsang, D
dc.contributor.authorWagstaff, J
dc.contributor.authorParmar, M
dc.date.accessioned2016-01-22T13:56:43Zen
dc.date.available2016-01-22T13:56:43Zen
dc.date.issued2015-12-21en
dc.identifier.citationAddition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 2015: Lanceten
dc.identifier.issn1474-547Xen
dc.identifier.pmid26719232en
dc.identifier.doi10.1016/S0140-6736(15)01037-5en
dc.identifier.urihttp://hdl.handle.net/10541/594615en
dc.description.abstractLong-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting first-line long-term hormone therapy. We report primary survival results for three research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to standard of care versus standard of care alone.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Lancet (London, England)en
dc.titleAddition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.en
dc.typeArticleen
dc.contributor.departmentWarwick Medical School, University of Warwick, Coventry, UKen
dc.identifier.journalLanceten
refterms.dateFOA2020-04-21T13:35:02Z
html.description.abstractLong-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting first-line long-term hormone therapy. We report primary survival results for three research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to standard of care versus standard of care alone.


Files in this item

Thumbnail
Name:
531041.pdf
Size:
693.9Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record